MX380989B - Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo. - Google Patents

Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo.

Info

Publication number
MX380989B
MX380989B MX2018009741A MX2018009741A MX380989B MX 380989 B MX380989 B MX 380989B MX 2018009741 A MX2018009741 A MX 2018009741A MX 2018009741 A MX2018009741 A MX 2018009741A MX 380989 B MX380989 B MX 380989B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition containing
kinase inhibitor
Prior art date
Application number
MX2018009741A
Other languages
English (en)
Other versions
MX2018009741A (es
Inventor
Hao Chen
Xiaochen Pan
Yun Lu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018009741A publication Critical patent/MX2018009741A/es
Publication of MX380989B publication Critical patent/MX380989B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente invención se proporciona una composición farmacéutica que contiene un inhibidor de la Janus quinasa ( JAK) o una sal farmacéuticamente aceptable del mismo. En particular, en la presente invención se proporciona una composición farmacéutica que contiene (3aR,5s, 6aS)- N-(3- metoxi- 1, 2, 4- tiadiazol- 5- il)-5-( metil(7H-pirrolo[ 2, 3- d] pirimidina-4- il)amino)hexahidrociclopenta[ c] pirrol-2( 1 H)- carboxamida, o una sal farmacéuticamente aceptable de la misma, y éter de celulosa. La composición farmacéutica de la presente invención se caracteriza por una tasa de disolución rápida y buena estabilidad.
MX2018009741A 2016-02-19 2017-02-17 Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo. MX380989B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610094168 2016-02-19
PCT/CN2017/073869 WO2017140254A1 (zh) 2016-02-19 2017-02-17 一种含有jak激酶抑制剂或其可药用盐的药物组合物

Publications (2)

Publication Number Publication Date
MX2018009741A MX2018009741A (es) 2018-11-09
MX380989B true MX380989B (es) 2025-03-12

Family

ID=59624719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009741A MX380989B (es) 2016-02-19 2017-02-17 Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo.

Country Status (12)

Country Link
US (1) US10786507B2 (es)
EP (1) EP3417861B1 (es)
JP (1) JP6875407B2 (es)
KR (1) KR20180109992A (es)
CN (1) CN107530348B (es)
AU (1) AU2017220971A1 (es)
BR (1) BR112018015369A2 (es)
CA (1) CA3014090A1 (es)
MX (1) MX380989B (es)
RU (1) RU2744432C2 (es)
TW (1) TWI745349B (es)
WO (1) WO2017140254A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293319B1 (en) 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
TW201827436A (zh) * 2017-01-20 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種jak激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN114727965B (zh) * 2019-12-23 2023-12-12 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂药物组合物
BR112022010101A2 (pt) * 2019-12-31 2022-09-06 Pfizer R&D Uk Ltd Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112023001283A2 (pt) 2020-07-28 2023-02-14 Arcutis Biotherapeutics Inc Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
US20230414511A1 (en) 2020-11-17 2023-12-28 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
TW202227452A (zh) * 2020-12-04 2022-07-16 大陸商廣州費米子科技有限責任公司 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途
CN113813228B (zh) * 2021-10-11 2023-04-18 北京鑫开元医药科技有限公司 一种具有jak激酶抑制活性的注射液及其制备方法和用途
CN118632687A (zh) 2021-11-11 2024-09-10 阿尔库缇斯生物疗法股份有限公司 用于深层皮肤药物递送的螺内酯药物组合物
EP4447930A1 (en) 2021-12-15 2024-10-23 Arcutis Biotherapeutics, Inc. Stable formulations of shr0302
CN120641104A (zh) * 2023-02-07 2025-09-12 瑞石生物医药有限公司 一种局部给药的药物组合物、其制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途
CN104470927B (zh) * 2013-06-07 2016-05-04 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐及其制备方法
CN105566327A (zh) 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
SI3216790T1 (sl) 2014-11-05 2020-02-28 Jiangsu Hengrui Medicine Co., Ltd., Kristalinična oblika bisulfata inhibitorja JAK-kinaze in postopek priprave le-te

Also Published As

Publication number Publication date
EP3417861B1 (en) 2020-09-23
KR20180109992A (ko) 2018-10-08
WO2017140254A1 (zh) 2017-08-24
CN107530348B (zh) 2020-10-20
TW201729812A (zh) 2017-09-01
CA3014090A1 (en) 2017-08-24
RU2744432C2 (ru) 2021-03-09
TWI745349B (zh) 2021-11-11
US20190030033A1 (en) 2019-01-31
AU2017220971A1 (en) 2018-08-02
JP2019505525A (ja) 2019-02-28
RU2018129775A (ru) 2020-03-19
EP3417861A4 (en) 2019-09-18
MX2018009741A (es) 2018-11-09
EP3417861A1 (en) 2018-12-26
US10786507B2 (en) 2020-09-29
BR112018015369A2 (pt) 2018-12-18
RU2018129775A3 (es) 2020-05-25
HK1244704A1 (zh) 2018-08-17
CN107530348A (zh) 2018-01-02
JP6875407B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
MX2018009741A (es) Composicion farmaceutica que contiene un inhibidor de janus quinasa o una sal farmaceuticamente aceptable del mismo.
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
ZA202103587B (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MX380928B (es) Inhibidores de kras g12c.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
MX2015016513A (es) Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
PH12017500724A1 (en) Carbazole derivatives
WO2016109217A3 (en) Btk inhibitors
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
MX384146B (es) Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
HK1252549A1 (zh) 控释tozadenant制剂
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.